On July 26, 2023, the Prostate Health Education Network (PHEN) partnered with the Memorial Sloan Kettering Cancer Center (MSKCC) for an informative Clinical Trials Learning Session. The session was spearheaded by PHEN’s Director of Clinical Trials and Patient Education Dr. Keith Crawford. It featured MSKCC’s Genitourinary Oncologist Dr. Andrew Laccetti as the main speaker.
ADream: a clinical trial is being conducted to determine if men with metastatic hormone sensitive prostate cancer (mHSPC) receiving intermittent ADT have fewer adverse events and poor quality of life (QOL) associated with continuous ADT.
AMG509: a clinical trial that investigates how well patients with metastatic castration-resistant prostate cancer (mCRPC) respond to a targeted prostate cancer immunotherapy.
PROMISE Registry: a prostate cancer registry conducted in the US, which offers 5,000 prostate cancer patients free at-home genetic testing.
In his opening remarks, Dr. Crawford emphasized the importance of increasing participation by African American men in clinical trials. He pinpointed a crucial issue: most clinical trials primarily focus on European ancestry, potentially overlooking unique genetic factors in Black men that could impact prostate cancer treatments.
The attendees had a more robust grasp of immuno-oncology and its role in targeting prostate cancer cells.